NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Svelte™ Medical Systems, Inc. is pleased to announce that it has completed 6 month follow up in its initial clinical trial with the Svelte Acrobat angioplasty system. The Svelte Acrobat is a low profile “All in One” stenting system with balloon control technology designed to reduce time and cost and improve safety in an angioplasty procedure. “This is truly a significant milestone for the Company. We are very pleased to see the excellent clinical results” said Mark Pomeranz, President and CEO of Svelte Medical Systems, Inc.
Doctor Alexandre Abizaid Chief of Coronary Interventions at Institute Dante Pazzanese de Cardiologia, Sao Paulo, Brazil noted, “The system has the ability to reduce time and costs in a procedure by allowing more lesions to be treated without pre-dilatation. The small size and flexibility of the system are well suited for the radial access approach.” The results of the trial will be presented at upcoming international congresses.
The company has recently initiated commercial activities in Europe since receiving the CE Mark last year and plans to begin US clinical trials on the technology in 2011. The company has a drug eluting version under development using a novel non-inflammatory bio-erodible carrier for the drug.
The company and the product are highlighted on the Company website at www.sveltemedical.com.
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company’s products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.